It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumor necrosis factor-α-induced protein 8 (TNFAIP8) expression has been linked to tumor progression in various cancer types, but the detailed mechanisms of TNFAIP8 are not fully elucidated. Here we define the role of TNFAIP8 in early events associated with development of hepatocellular carcinoma (HCC). Increased TNFAIP8 levels in HCC cells enhanced cell survival by blocking apoptosis, rendering HCC cells more resistant to the anticancer drugs, sorafenib and regorafenib. TNFAIP8 also induced autophagy and steatosis in liver cancer cells. Consistent with these observations, TNFAIP8 blocked AKT/mTOR signaling and showed direct interaction with ATG3-ATG7 proteins. TNFAIP8 also exhibited binding with fatty acids and modulated expression of lipid/fatty-acid metabolizing enzymes. Chronic feeding of mice with alcohol increased hepatic levels of TNFAIP8, autophagy, and steatosis but not in high-fat-fed obese mice. Similarly, higher TNFAIP8 expression was associated with steatotic livers of human patients with a history of alcohol use but not in steatotic patients with no history of alcohol use. Our data indicate a novel role of TNFAIP8 in modulation of drug resistance, autophagy, and hepatic steatosis, all key early events in HCC progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703)
2 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703); Ningxia Medical University, Ningxia Hui Autonomous Region, Yinchuan, China (GRID:grid.412194.b) (ISNI:0000 0004 1761 9803)
3 North Carolina Central University Durham, Department of Pharmaceutical Sciences, Bio-manufacturing Research Institute and Technology Enterprise (BRITE), Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703)
4 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703); North Carolina Central University Durham, Department of Pharmaceutical Sciences, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703)